Drug Trial Radar · NCT05217303
HL-085 in NRAS-mutated Advanced Melanoma
Last checked: Nov 19, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Nov 2, 2020
Primary completion
Feb 19, 2023
Study completion Feb 20, 2023
Sponsor
- Lead sponsor
- Shanghai Kechow Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label, single-arm, multi-center phase II clinical study, aimed at investigating the efficacy and safety of HL-085 capsule in the treatment of advanced melanoma patients with NRAS mutation.
Conditions
- Melanoma
Interventions
HL-085Drug
HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- objective response rate (ORR)Time frame: through study completion, an average of 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Beijing Oncology Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.